The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polj), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative pold and pola, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polj transcription. Finally, we found that polj downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours.
Introduction
DNA replication of the genome is promoted by a wellorchestrated machinery including the error-free 'replicative' polymerases d and e (pold and pole) as well as the primase pola. Furthermore, evolution has selected errorprone polymerases, named 'specialized' or 'translesional (TLS) (Hubscher et al., 2002; Lehmann, 2003) . Their role could be to process DNA damage by promoting either translesion or the DNA synthesis step that follows excision of DNA adducts or synapses of DNA breaks.
In clinical specimens from different stages of human tumours, the precursor lesions commonly express markers of a 'DNA replication stress' such as DNA breaks (Bartkova et al., 2005; Gorgoulis et al., 2005) . As the specialized DNA polymerases are often misregulated in human cancers (Albertella et al., 2005) , we propose that an unbalance between these enzymes and replicative polymerases could contribute to these early genetic disorders. We have already shown that misregulation of polb, k or l perturbs both DNA replication and DNA double-strand break (DSB) repair, favouring carcinogenesis (Bergoglio et al., 2002 (Bergoglio et al., , 2003 Servant et al., 2002; Bavoux et al., 2005b; Capp et al., 2006) .
Polk is the human homologue of the Escherichia coli DinB (pol IV) protein, which is known for decades as part of the inducible 'SOS' system. Polk belongs to the Y family of specialized DNA polymerases (polk, i, Z, Rev1) which gained high interest with the discovery of a deficiency of polZ in the skin cancer predisposing syndrome xeroderma pigmentosum variant. The main putative physiological role currently attributed to polk is to replicate accurately in vitro thymine glycol, 8oxoG and aromatic adducts such as benzo [a] pyrene diol epoxide (BPDE) (Bavoux et al., 2005a) . Recently, it has also been shown that POLK-deficient cells have reduced levels of nucleotide excision repair (NER) (Ogi and Lehman, 2006) , suggesting a role of polk in the final NER DNA gap-filling step. Downexpression of polk may therefore affect not only the efficiency of the accurate bypass of DNA lesions but also the accurate NER of bulky adducts, resulting in both cases in DNA disorders. This suggests the need for a tight regulation of this enzyme in order to avoid genetic instability. We report here the decreased level of polk transcripts in human colorectal tumours, whereas the expression of the replicative pold remained nearly unchanged. These observations pushed us to identify the DNA elements responsible for transcriptional modulation of the POLK gene expression.
We determined stimulating protein-1 (SP1) and activating transcription factor (ATF)/cyclic AMPresponsive element (CRE) as cis-elements that modulate the transcriptional activation of the POLK promoter. We also show that ectopic expression of either SP1/SP3 or CRE-binding protein (CREB) promotes polk transcription. Moreover, we show that in polk downexpressing colorectal biopsies, SP1 and CREB are also downexpressed. These data suggest that in the course of the increasing genetic variability of cancer cells, the specialized 'repair' polk could be 'silenced' by downregulation of CREB and SP1 transcription factors.
Results

Pol k is downregulated in colorectal cancer
In order to assess the transcriptional expression of polk in colorectal cancer, we have quantified the levels of transcripts extracted from non-tumoral/tumoral coupled biopsies extracted from 74 patients who had not received any therapy before surgery. Figure 1 indicates that while the expression of the replicative pold as well as pole (not shown) remained almost unchanged in most of the tumours, polk was mainly downexpressed since 48.6% (36/74) and 32.4% (24/74) tumour biopsies showed a level of transcripts more than 1.5-and 2-fold lower respectively, when compared with adjacent tissues (Figure 1) . Moreover, 9.4% (7/74) tumours displayed polk levels more than fourfold lower than controls, whereas such unbalance was not observed in the case of pold.
Inhibition of histone deacetylation induces polk expression
Gene expression in mammalian organisms is regulated at multiple levels, including chromatin accessibility for transcription factors. We first looked in the POLK promoter for the presence of CpG islands, known to repress transcription when methylated. The CpG Island Searcher program (http://cpgislands.usc.edu/) helped us to identify a 2-kb-long CpG island (CpG/GpC of 0.815, %GC of 58.8) running from the À1413 to þ 22 position (Figure 2b ). We analysed whether inhibition of methylation could induce polk expression in human colorectal cancer RKO cells. As a positive control, we verified that the expression of the mismatch repair hMLH1 gene was inhibited by methylation as already reported (Hernan et al., 1998) . Exposure to either 4.3 mM (Figure 2a ) or 8.6 mM (not shown) 5-aza-C demethylating reagent did not lead to a significant induction of polk mRNA, whereas such treatment induced the re-expression of hMLH1. To confirm such results, we used the sodium bisulphite method (Hernan et al., 1998) to analyse the methylation status of genomic DNA extracted from some non-tumoral or tumoral cell lines (IMR90, RKO, MRC5, A548) for which no detectable expression of polk was found (data not shown). Figure 2b shows that no methylation was detectable among the 32 CpGs included in a 312-nt region around the transcription start site. Absence of CpG methylation was also observed in MRC5-SV lung fibroblasts (Figure 2b ) as well as in other human immortalized cell lines or tumour biopsies (data not shown). These data show that polk expression is not modulated by promoter methylation. Figure 1 Relative expression ratios of polk and pold transcripts in 74 colorectal tumour biopsies. The 74 coupled biopsies were obtained from fresh surgical resection. The level of transcripts was measured in triplicate by using the LDA technology. To normalize, four control genes (18S, GAPDH, HPRT, YWHAZ) were amplified from each cDNA. The two most stable control genes were determined and used by qBase to normalize the expression values. T (tumour)/N (non-tumoral) mRNA expression ratios between normalized values were calculated. T/N values lower than 1 were transformed to the inverse value N/T. þ and À indicate that the expression is higher or lower, respectively, in the tumour sample than in the adjacent control tissue.
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Post-translational modification of histones also contributes to modulation of chromatin accessibility. Therefore, we treated cells with the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) and found that contrary to 5-aza-C, exposure to either 0.3 mM (Figure 2a ) or 0.6 mM (not shown), TSA led to a significant 5-to 8-fold induction of endogenous polk transcripts. Interestingly, the expression of either errorfree replicative pola or d was not modified by this treatment. This result indicates that the transcription of the error-prone polk is activated by factors sensitive to HDAC inhibitors.
The POLK promoter contains cis-modulating elements
The presence of cis-regulating regions in the POLK promoter was then explored. Promoter fragments from positions À995, À907, À860, À497, À395, À301, À237, À174, À122 and À83 to the position þ 22 (end of the 5 0 UTR region) were cloned upstream a luciferase reporter gene and assessed for their transcriptional activity in either colon cancer RKO or immortalized lung fibroblast MRC5-SV cells (Figure 3 ). The expression pattern was very similar whichever strain we used. In both strains, the transcriptional activity of the fragment pGL3-83 (the smallest) was 2-to 4-fold increased by the elements located between À83 and À237. This maximal activity was dramatically reduced by the addition of elements between À395 and À860. Our findings then indicate that the promoter region downstream of À237 contains cis-activating elements, whereas a region situated upstream of À395 harbours cis-inhibiting sites that alter the transcriptional activity.
Polk transcription depends on CRE and SP1 elements
The MatInspector and Genomatix programs (http:// www.genomatix. de/) identified transcriptional elements in the TATA-less POLK promoter (Figure 4 ), including two that are commonly found associated with such promoters, i.e. SP1 (two regions) and NFkB-binding sites, which are situated in the activator region ( Figure 3 ). We also identified two CRE-binding elements, also found in many TATA-less promoters, which are situated in the À237/À122 activating domain, as well as one SMAD site in the inhibiting region situated upstream of the position À395. To investigate the role of these six elements in the modulation of the transcriptional activity, each of them was inactivated by directed mutagenesis. Modification of the À431 SMAD, À201 SP1, À156 NFkB and À118 CRE-binding sites did not modify the luciferase expression ( Figure 4, lanes 2, 4, 7, 8 ). In contrast, mutation of either the À180 CRE (lane 5) or À78 SP1 (lane 10) elements significantly affected the transcription. Regarding these data, we followed our investigations by focusing on these two elements.
The CRE element is involved in activation of the POLK promoter To confirm that CRE plays a role in promoter activation, we then examined DNA-binding activity in RKO nuclear cell extracts at the ATF/CRE site by using double-stranded DNA harbouring either a consensus site, known to bind the CREB protein (Feng et al., 2004) , the POLK wild-type CRE (À180) or a mutated sequence. Electrophoretic mobility shift assays (EMSA) band shift assays (Figure 5a ) revealed a major band when the radiolabelled probe carried either the consensus (lanes 2, 7) or the wild-type (lane 3) CRE site. This band was abolished by preincubation with a molar excess of cold consensus probe (lane 4). It also disappeared when using the probe encoding the mutated CRE site (lane 5), suggesting that a protein included in the RKO cell extracts bound the POLK CRE site. We then cotransfected RKO cells with both a pSV-CREB expression vector, and either the full-size promoter region (pGL3-1413) or a pGL3-237 vector harbouring a 237-bp-long CRE (À180)-containing promoter region, both fused in frame with the luciferase marker. Figure 5b reveals that in both cases, the ectopic CREB expression dramatically induced the luciferase activity, suggesting that CREB is associated with enhanced transcription, probably after binding the CRE (-180) POLK element.
The SP1 element is involved in activation of the POLK promoter To examine whether the SP1 family modulates the promoter expression, we performed similar EMSA assays. Four bands (I, II, III, IV) were detected ( Figure 6a ) when protein extracts prepared from RKO cells were incubated with either the consensus element known to bind SP1 as well as SP3 proteins (Shin et al., 2005) Regulation of the cancer-associated DNA polymerase j
The three upper bands (I, II, III) disappeared either when the mutated SP1 sequence was used (lanes 6, 7) or when the DNA-protein complexes were incubated in the presence of a competitor (lane 5). These data suggest that proteins from DNA-proteins complexes I, II and III bound the wild-type SP1 (À78) as well as the consensus SP1 site. We also cotransfected RKO cells with either a pCMV-SP1 or pCMV-SP3 expression plasmid as well as a pGL3-122 plasmid harbouring a SP1 (À78)-containing promoter region fused in-frame with the luciferase gene. Figure 6b indicates that ectopic expression of either SP1 or SP3 increased by more than twofold the luciferase level expressed by the truncated promoter. A similar induction was found when using the full-sized 1413-bp-long promoter region. As an additional control, we also incubated RKO cells transfected with the pGL3-122 plasmid with mithramycin A (MTA), known to inhibit the interaction of SP factors with GC-rich regions such as SP1 site (Ray et al., 1989) .
We found that MTA significantly reduced the activity of the promoter (Figure 6b ), further supporting that the SP1 (À78) site plays a role in polk activation, probably by recruiting SP1 or SP3 proteins.
CREB and SP1 are downregulated in polk underexpressing colorectal biopsies In order to evaluate if downregulation of polk expression in the colorectal cancer collection is associated with a decreased in CREB and/or SP1 expression, we measured the levels of mRNA in 11 polk-downexpressing colorectal tumours. We found that in all these coupled biopsies, both CREB and SP1 transcripts were down-expressed in tumours compared with the adjacent non-tumoral tissues. In contrast, CREB and SP1 expression remained stable in five tumours for which polk level was unchanged or slightly overexpressed (Figure 7 ). Regulation of the cancer-associated DNA polymerase j F Lemée et al
Discussion
The major role of Y-pols is to carry TLS past damaged bases. Aside from this function, polk has been recently shown to be surprisingly involved in repair synthesis as knock-out mouse cells display a reduced NER level (Ogi and Lehman, 2006 (Velasco-Miguel et al., 2002; Bavoux et al., 2005a) , suggesting that the expression of this enzyme is intrinsically regulated. We show here that contrary to replicative polymerases, the TATA less promoter of POLK contains both activating and inhibiting domains. We also found that the SP1 (À78) and ATF/CRE (-180) elements are involved in expression of the POLK gene, probably after binding SP1/SP3 and CREB transcription factors, respectively. While the SP1 family includes ubiquitous transcription factors that modulate the expression of multiple genes (Briggs et al., 1986) , the proteins of the CREB family have been shown to regulate DNA repair genes such as BRCA1 (Atlas et al., 2001) . Moreover, the CRE element of the specialized polb is essential for its transcriptional activation as well as response of cells to alkylating treatments (Kedar et al., 1991) .
Our data also indicate that the transcription of polk is activated by factors sensitive to TSA, an inhibitor of histone deacetylation. These factors could not only be acetylated histones by themselves but also several other acetylated proteins. Indeed acetylation of lysine residues within non-histone proteins, including transcription factors such as p53, EKLF, MyoD, E2F or NFkB, is admitted as a major mechanism to regulate protein-DNA interactions and overcome the repressive action of a b
Figure 5 DNA-binding activity at the CRE site (a) and promoter activity after transient expression of CREB (b). (a) EMSA were performed using RKO nuclear extracts and dsDNA harbouring either a consensus site (CRE-Cons), the POLK wild-type CRE (À180) element (POLK-CRE (À180) WT) or a mutated sequence (POLK-CRE (À180) Mut). To show the specificity of the bands, a 25 Â molar excess of cold double-stranded oligonucleotide carrying the consensus CRE site was used for competition. NE: nuclear RKO extracts. (b) RKO cells were cotransfected with the pSV-CREB expression vector and a reporter luciferase plasmid carrying either the truncated (pGL3-237) or the full-sized (pGL3-1413) POLK promoter. Each luciferase reporter construct was cotransfected in RKO cells with the pRL-CMV plasmid. The horizontal axis shows the RLU of luciferase to renilla activity normalized by the RLU ( ¼ 1) displayed by cells cotransfected with the empty pSV vector and each pGL3 construct (n>4 per construct).
Regulation of the cancer-associated DNA polymerase j F Lemée et al packaged higher-order DNA structure (Bannister and Miska, 2000; Chen and Greene, 2003) . In our experiment, TSA may thus either modify a transcription factor or directly modulate the post-translational modifications of CREB and SP1, leading to an increased expression of polk.
a b
Figure 6 DNA-binding activity at the SP1 site (a) and promoter activity after transient expression of SP1 and SP3 (b). (a) EMSA were performed using RKO cell extracts and dsDNA harbouring either a consensus site (Sp1-Cons), the POLK wild-type Sp1 (À78) element (POLK-Sp1 (À78) WT) or a mutated sequence (POLK-Sp1 (À78) Mut). To show the specificity of the bands, a 25 Â molar excess of cold double-stranded oligonucleotide carrying the wild-type SP1 site was used for competition. NE: nuclear RKO extracts. (b) RKO cells were cotransfected with the pCMV-SP1 or pCMV-Sp3 expression vectors and a reporter luciferase plasmid carrying either or the truncated (pGL3-122) or the full-sized (pGL3-1413) POLK promoter. Each luciferase reporter construct was cotransfected in RKO cells with the pRL-CMV plasmid. The horizontal axis shows the RLU of luciferase to renilla activity normalized by the RLU ( ¼ 1) displayed by cells cotransfected with the empty pSV vector and each pGL3 construct (n>4 per construct). RKO cells transfected with either pGL3-122 or pGL3-1413 were also treated with 100 nM MTA. The horizontal axis shows the RLU of luciferase to renilla activity normalized by the RLU ( ¼ 100%) displayed by untreated pGL3/pRL-CMV cells (n>4). Figure 7 Compared ratios of polk vs CREB/SP1 mRNA expression in colorectal tumours. Biopsies known to underexpress polk (no. 11, 25, 34, 37, 50, 51, 52, 55, 56, 59 , 64) compared with adjacent non-tumoral tissues were assessed for expression of CREB and SP1 transcripts. As controls, the expression was also evaluated in coupled biopsies where POLK expression is not misregulated (no. 1, 4, 6, 57, 60) . T/N mRNA expression ratios between normalized values were calculated. T/N values lower than 1 were transformed to the inverse value N/T. þ and À indicate that the pol expression is higher or lower, respectively, in the tumour sample than in the adjacent control tissue.
Recent data indicate that cancer-associated genetic disorders emerge from an early replication stress in hyperplasic colorectal tissues (Bartkova et al., 2005; Gorgoulis et al., 2005) . The specialized DNA polymerases being involved in most of error-free DNA repair processes, we make the assumption that they could contribute to these early genetic disorders when downexpressed. Microarray analyses in tumours from the kidney, breast, prostate, uterus, lung and stomach show that polk is rarely overexpressed but commonly underexpressed (lbertella et al., 2005) . After investigating the expression of polk in 74 homogenous matched normal and tumour colorectal biopsies, we present data showing that a large part of them poorly express polk compared with adjacent non-tumoral tissues, whereas the levels of replicative pold and e remain almost unchanged. We propose that in the course of the evolution, polk has evolved from an error-prone DNA polymerase (DinB or polIV in E. coli) to an enzyme specialized in accurate functions such as the error-free bypass of some DNA damage (Bavoux et al., 2005a) or NER (Ogi and Lehman, 2006) . This idea is supported by the presence of polk foci in untreated cells, suggesting a role in key accurate DNA transaction (Bergoglio et al., 2002; Ogi et al., 2005) . Cancer cells could therefore tend to inhibit such error-free DNA transactions with the aim to enhance genetic instability, via the silencing of the 'repair' polk. The present study suggests that in some tumours, decreased levels of CREB and to a lesser extent, SP1 proteins could contribute to such silenced expression of polk. However, as inhibition of histone deacetylation also modulated polk repression, we cannot exclude a double involvement of epigenetic alteration and regulation in trans. Such connection has been already shown regarding the mismatch repair Mlh1 whose expression can be either epigenetically regulated in colorectal cancer (Hernan et al., 1998) or mediated by transcription factors such as E2F (Iwanaga et al., 2004) , NF-Y (Arita et al., 2003) or HOXA5 (Duriseti et al., 2006) .
In conclusion, we propose that a decreased expression of polk, which is apparently a common event in tumours, could be a genetic instability enhancer process. Transcription factors, such as those identified in this study could reflect an unbalance between specialized and conventional DNA polymerases and be considered as potential prognostic cancer markers.
Materials and methods
Tissue specimen, RNA extraction and PCR analysis Tissue specimens from 74 patients (>50 years) freshly surgically treated for colorectal adenocarcinoma without adjuvant therapy and without microsatellite instability were selected from the tissue bank of Purpan hospital (Toulouse, France). All the disease stages were equally represented. The extraction procedure as well as the RNA quantification is described in the Supplementary materials.
5-Aza-2
0 -deoxycytidine and TSA treatments RKO cells were seeded at a density of 300 Â 10 3 cells/60-mm dish, and allowed to attach over 24 h then 4.3 mM 5-aza-2 0 -deoxycytidine (Sigma, France) or 300 nM TSA (Sigma) was added to the medium for 3 days. At every 24 h interval, fresh medium containing the drug was added. RNA was then extracted using the RNeasy Minikit (Qiagen, France), then checked by capillary electrophoresis. Complementary DNAs were synthesized using the ThermoScript reverse transcriptase-polymerase chain reaction (RT-PCR) system (Invitrogen, France), following the manufacturer instructions and RT-PCR was then performed by using probes specific to human POLK, POLD, POLA and hMLH1 (assay ABI cat. no. Hs00179866 from Applied, France). The SYBR Green PCR Master Mix was used for the amplifications of the control genes as described above.
Bisulphite modification of genomic DNA for analysis of DNA methylation status DNA was extracted, denatured and treated with bisulphite as described (Anacleto et al., 2005) . To check the modification by sodium bisulphite, methylation of the promoter of hMLH1 gene was analysed as already described (Anacleto et al., 2005) by using the methylation-specific PCR method (Herman et al., 1996) through amplification with two sets of primer (see Supplementary materials) designed for unmethylated and methylated sequences.
Expression vectors
To clone the full-size promoter of POLK in the firefly luciferase reporter pGL3 (Promega, France) vector, we performed a PCR by using the BAC RP-144A5 (Invitrogen) as a template and the NheI-containing forward 5 0 -CTA GCTAGCATCAGTCTCCATTCTCACAT-3 0 and HindIIIcontaining reverse 5 0 -CCCAAGCTTCCGTTACCTCAGGA TCG-3 0 primers. The PCR product was inserted into pGL3 digested by NheI and HindIII to give the construction pGL3-1413. This pGL3-1413 vector was used as a template for the cloning of serially deleted POLK promoter reporter vectors by using the same reverse primer and the forward primers described in Supplementary materials. Directed mutagenesis was carried out by following the DpnI-based Quick Change site-directed mutagenesis (Stratagene, France) methodology. Mutation-containing primers are given in the Supplementary materials. The pCMV-Sp1 and pCMV-Sp3 expression vectors were generous gifts from Dr Schaak (INSERM U388, France). The pSV-CREB plasmid was kindly provided by Dr P SassoneCorsi (IGBMC, CNRS, Strasbourg, France).
Cell culture, transfections and luciferase reporter assay Conditions for cell culture, transfections as well as luciferase assays are described in the Supplementary materials.
Electrophoretic mobility shift assays EMSA procedure and preparation of DNA probes are described in the Supplementary materials.
